



Smith, CM; Lessells, R; Grant, AD; Herbst, K; Tanser, F (2017) Spatial clustering of drug-resistant tuberculosis in Hlabisa subdistrict, KwaZulu-Natal, 2011-2015. The international journal of tuberculosis and lung disease, 22 (3). pp. 287-293. ISSN 1027-3719 DOI: https://doi.org/10.5588/ijtld.17.0457

Downloaded from: http://researchonline.lshtm.ac.uk/4646799/

DOI: 10.5588/ijtld.17.0457

Usage Guidelines

 $Please \ \ refer \ \ to \ \ usage \ \ guidelines \ \ at \ \ \ http://research on line.lshtm.ac.uk/policies.html \ \ or \ \ alternatively \ contact \ research on line@lshtm.ac.uk.$

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/

- 1 Title
- 2 Spatial clustering of drug-resistant tuberculosis in Hlabisa sub-district, KwaZulu-Natal, 2011-
- 3 2015
- 4 Catherine M Smith
- 5 Department of Public Health Informatics, Institute of Health Informatics, UCL
- 6 Richard Lessells
- 7 Department of Clinical Research, London School of Hygiene and Tropical Medicine
- 8 Africa Health Research Institute, Somkhele, South Africa
- 9 Alison Grant
- 10 Department of Clinical Research, London School of Hygiene and Tropical Medicine
- 11 Africa Health Research Institute, School of Nursing and Public Health, University of
- 12 KwaZulu-Natal, South Africa
- 13 School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
- 14 Kobus Herbst
- 15 Africa Health Research Institute, Somkhele, South Africa
- 16 Frank Tanser
- 17 Africa Health Research Institute, Somkhele, South Africa
- 18 School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
- 19 Centre for the AIDS Programme of Research in South Africa CAPRISA, University of
- 20 KwaZulu-Natal, Congella, South Africa.
- 21 Running head
- 22 Spatial clusters of tuberculosis in KwaZulu-Natal
- 23 **Summary** 199 words
- 24 **Body**: 2499
- 25 **References**: 34
- 26 **Tables**: 1
- 27 **Figures**: 3

28 Keywords

29 Geographical information systems, disease clustering, HIV infections

30 **SUMMARY**

- 31 Setting
- 32 Incidence rates of tuberculosis in South Africa are amongst the highest in the world, and
- drug-resistance is a major concern. Understanding geographic variation in disease may
- 34 guide targeted interventions.
- 35 Objective
- We aimed to characterise the spatial distribution of drug-resistant tuberculosis (DRTB) in a
- rural area of KwaZulu-Natal, South Africa, and test for clustering.
- 38 Design
- 39 This was a cross-sectional analysis of DRTB patients managed at a rural district hospital
- 40 from 2011-2015. We mapped all patients in hospital data to local areas; and linked to a
- 41 population-based demographic surveillance system to map patients to individual
- 42 homesteads. We used kernel density estimation to visualise the distribution of disease and
- 43 tested for clustering using spatial scan statistics.
- 44 Results
- There were 489 patients with DRTB in the sub-district; 111 lived in the smaller demographic
- 46 surveillance area. Spatial clustering analysis identified a high-risk cluster (relative risk of
- DRTB within cluster compared to outside: 3.0, p<0.001) in the south-east, a region
- characterised by high population density and high HIV prevalence.
- 49 Conclusion
- 50 We have demonstrated evidence of a geographic high risk cluster of DRTB. This suggests
- 51 that targeting interventions to spatial areas of highest risk, where transmission may be
- 52 ongoing, could be effective.

INI.	TD	^	n	IO.	TI.	$\boldsymbol{\smallfrown}$	NI
III	IΚ	v	טע	JC.	H	U	IN

54 55 Incidence rates of tuberculosis (TB) in South Africa are amongst the highest in the world.¹ In 2015 there were an estimated 454,000 new diagnoses, a rate of 834 per 100,000 56 population, and it is the leading natural cause of death in the country.^{1,2} Rates of TB are 57 particularly high in the province of KwaZulu-Natal, largely driven by the high prevalence of 58 human immunodeficiency virus (HIV) and complicated by TB drug resistance.^{3,4} 59 Understanding the spatial distribution of disease is important for effective control. Spatial 60 analyses can be used to identify the worst affected areas, generate hypotheses about 61 transmission, and guide interventions.⁵ Tests of spatial clustering can be used to identify 62 groups of patients that occur closer together in space than would be expected by chance. 63 These analyses have been used to identify areas of likely TB transmission. 6-14 Visualisation 64 of spatial data on maps also provides a powerful means of communicating information about 65 66 the disease to policy makers and the public. 67 The Africa Health Research Institute (AHRI) in the Hlabisa sub-district of KwaZulu-Natal, 68 South Africa, maintains a large health and demographic surveillance system. This includes 69 individual residential locations mapped to an accuracy of less than two metres, and routine linkage to public sector records. 15, 16 The aim of this study was to characterise the spatial 70 distribution of drug-resistant TB (DRTB) in the sub-district, test for spatial clustering, and 71 discuss implications for prevention and care. 72 STUDY POPULATION AND METHODS 74 75 Study area

- Hlabisa health sub-district is an area of approximately 1,450km² and 247,350 residents in 76
- 77 uMkhanyakude district, northern KwaZulu-Natal, South Africa (Figure 1A). It is characterised
- by high prevalence of HIV with high rates of associated TB (577 recorded TB cases per 78
- 100,000 population in uMkhanyakude in 2015; 64.3% HIV positive).^{3, 17} The AHRI 79
- demographic surveillance area is located within the Hlabisa sub-district (Figure 1B). This a 80
- region of 435km², with approximately 11,000 homesteads and 60,000 residents, in which 81
- AHRI has undertaken population-based demographic surveillance since 2000.¹⁵ 82
- 83 Data sources and identification of DRTB patients
- 84 This was a cross-sectional analysis of patients diagnosed with DRTB between 2011 and
- 85 2015 who were resident in the Hlabisa health sub-district. Since 2011, all patients with DRTB
- aged 12 years and older were admitted to the TB ward at Hlabisa hospital for at least the 86

87 first month of treatment. Since July 2013, individuals in the sub-district with DRTB have been 88 identified through Xpert MTB/RIF testing at one of 17 primary health care clinics. Prior to 89 that, most patients were identified through culture-based methods, apart from a small 90 number of patients diagnosed using Xpert MTB/RIF tests at a clinical trial site.¹⁸ 91 We identified patients with DRTB using ICD-10 discharge codes in the Hlabisa hospital 92 information system. We defined DRTB based on South African coding standards, incorporating codes for rifampicin mono-resistant, multidrug-resistant (MDR) and extensively 93 drug-resistant (XDR) TB.¹⁹ We calculated the proportion of patients in the hospital 94 admissions data who had DRTB, and described characteristics of patients. Data from the 95 96 hospital information system are routinely linked to the AHRI demographic surveillance data 97 using the South African identification number or through a standard probabilistic matching algorithm.¹⁵ We used linked data to identify individual homestead locations. 98 99 The research was approved by the Biomedical Research Ethics Committee of the University 100 of KwaZulu-Natal (ref. BE290/16), the Ethics Committee of the London School of Hygiene 101 and Tropical Medicine (ref. 11814), and the Health Research Committee of the KwaZulu-102 Natal Department of Health (ref. 378/16). These committees waived the requirement for 103 individual informed consent to use the hospital admissions data, as the data were routinely collected from hospital records and there was no direct interaction with individual patients. 104 105 Spatial analysis We conducted two spatial analyses which derived patient geographic locations using 106 107 different methods: a local area analysis which covered the entire Hlabisa sub-district; and a micro-geographic analysis using the precise locations of patient homesteads within the 108 109 smaller AHRI demographic surveillance area. 110 In the local area analysis, we compared the spatial distribution of DRTB patients with all 111 other hospital admissions. Local areas are informal regions used by local populations to describe the sub-district, and have been mapped by AHRI (315 local areas in the Hlabisa 112 sub-district in total, Figure 1B). We extracted patient-reported local areas of residence from a 113 free text field in the hospital data, and matched them to mapped names of local areas. 114 115 In the micro-geographic analysis, we compared point residential locations for patients with DRTB to the spatial distribution of the general population. We used residential locations from 116 the AHRI demographic surveillance data. For DRTB patients, we identified the exact 117 118 homestead of residence which was recorded in the surveillance system closest in time to the 119 patient's date of admission to Hlabisa hospital. The distribution of the general population was

120 121	derived by calculating total person years of residence in each homestead over the study period.
122 123 124	We tested for spatial clustering of DRTB in both the local area and micro-geographic analyses. We used spatial scan statistics, implemented in the SaTScan software, ²⁰ to test the hypothesis that DRTB patients were closer together in space than the underlying population distribution. Scan statistics are used to compare the observed number of cases
125 126 127 128 129 130 131	within spatial windows of various sizes with those that would be expected, in this case, under a random Poisson distribution. A likelihood ratio is calculated for each window which compares the observed and expected numbers of cases inside and outside the window. Monte Carlo simulations are then used to generate random distributions of cases under the Poisson distribution, which are compared to the observed data to calculate a p-value. We set the maximum cluster size to 3 km, because spatial dependencies have previously been reported for HIV within this distance in this study area. ²¹
133 134 135 136	We also plotted the locations of clusters on a smoothed map of the relative proportion of DRTB patients compared to the underlying distribution in continuous geographical space. These maps were produced using kernel density estimation with a standard Gaussian kernel of 3km radius.
137	Analyses were performed using R v 3.2.3, using the packages <i>spatstat</i> and <i>rsatscan</i> . ^{22, 23}
139 140 141 142 143	RESULTS Between 2011 and 2015, there were 19,408 individuals admitted to Hlabisa hospital who could be allocated to a local area in the Hlabisa sub-district. Of these, 489 (2.5%) had an ICD-10 hospital discharge code indicating DRTB, among whom the majority (478, 98%) had MDR disease.
144 145 146 147 148	Characteristics of patients with DRTB are shown in Table 1. Approximately half (250, 51%) the patients were female, and the modal age group was 25-34 years. There were 340 (70%) HIV positive DRTB patients, among whom 202 (60%) were on antiretroviral therapy at the time of admission. One in six (78, 16%) DRTB patients died prior to discharge, and five absconded from hospital.
149	Local area analysis of DRTB in the Hlabisa sub-district
150 151 152	We used the distribution of all 19,408 patients admitted to Hlabisa hospital across the local areas in the sub-district as a denominator for analyses of spatial clustering amongst the 489 DRTB patients.

There was one high relative risk cluster, located in the south-east of the sub-district (p<0.001). This cluster had a radius of 1.9 km, comprised four local areas with a total of 79 DRTB patients compared to 29 that would be expected by chance, and had a relative risk of 3.0. There was some evidence of a low relative risk cluster in the west of the sub-district, close to the hospital (p=0.08). This cluster had a radius of 2.1 km; comprised four local areas with six patients compared to 19 expected, and a relative risk of 0.3. Locations of these two clusters, overlaid on a smoothed map of the relative proportion of DRTB patients compared to all hospital admissions are displayed in Figure 2.

Micro-geographic analysis of DRTB in the AHRI demographic surveillance area

There were 144 DRTB patients whose hospital data could be linked to the AHRI population surveillance data. Of these, 111 had a recorded homestead location during the study period and were included in the analysis (94 patients had a residential location recorded in the same year as their admission date; 16 of the remaining patients had a residence recorded before their admission date, and one had a residence location recorded the year after their admission date). The remaining 33 patients were excluded from this analysis because they did not have a homestead of residence recorded during the period of this study (2011-2015).

The 111 patients with DRTB resided at 106 unique homestead locations; 10 patients shared homesteads with another patient. The most likely high relative risk cluster (p=0.057) had a radius of 2.8 km. The cluster comprised 55 patients compared to 31 that would be expected by chance, had a relative risk of 2.5, and all the homesteads with more than one patient were in this area. It was in a similar region to the high-risk cluster resulting from the local area-level analysis of the entire Hlabisa sub-district, in the south-east of the demographic surveillance area. This is the area around a township and is characterised by high population density and HIV prevalence compared to the rest of the demographic surveillance area.²¹ There were no low relative risk clusters identified in this analysis.

DISCUSSION

In this study, we have described the spatial distribution of DRTB in the Hlabisa sub-district of KwaZulu-Natal for the first time. DRTB was highly prevalent in this region, with 489 (2.5%) of inpatients at Hlabisa hospital affected over a five-year period. Almost all had MDR disease and 16% died in hospital. There was clear evidence of a geographic high risk cluster of DRTB in the south-east of the region. This area is characterised by relatively high population density and high incidence and prevalence of HIV.²¹ This spatial heterogeneity of DRTB in a high burden, predominantly rural area was consistent with findings from lower HIV

187 prevalence settings, although our analysis was at a more granular level than most previous studies. 6, 10, 11 188 Establishing the spatial distribution of disease in rural areas such as the Hlabisa sub-district 189 190 is challenging. This is because residential addresses are not recorded routinely in hospital 191 systems, many people live in informal settlements which are not accurately mapped, and the population is highly mobile.²⁴ A strength of our study is that we used precise residential 192 locations collected in the AHRI demographic surveillance system. We were therefore able to 193 194 derive the geographic distribution of DRTB from two different data sources: the self-reported local area of residence from hospital data, and, for residents of the AHRI demographic 195 196 surveillance area, the homestead of residence. High risk clusters of disease were indicated 197 in the same approximate area using both methods, suggesting that the observed clustering is genuine. 198 199 The area of spatial clustering was characterised by high population density, and only 10 200 (18%) patients in the cluster shared residences with other patients. This implies that 201 transmission of DRTB in this community may have occurred in public places as well as 202 within households. Other studies have also indicated the importance of community-based transmission of TB in similar settings. 12, 25-30 Indoor venues with poor ventilation in which 203 people come into close contact including healthcare facilities, public transport, churches and 204 205 bars have been implicated as possible areas of transmission. An important component of 206 DRTB prevention is therefore to identify such venues in the community and implement interventions including active case finding by regular screening; contact tracing; improving 207 208 access to treatment, and airborne infection control measures in health facilities. The distinct spatial clustering of the disease suggests that targeting these interventions to 209 210 suspected high transmission areas could be effective. However, our findings only reveal 211 where people with DRTB reside, and uncovering precisely where transmission is occurring will require more detailed clinical and molecular epidemiology. A prospective cohort of 212 people with DRTB is now operational in the study area where information is collected about 213 214 social contact patterns and use of shared public spaces. This will be integrated with whole genome sequence data to provide better understanding of transmission. 215 216 The results of our study also highlight the importance of the interaction between HIV and TB 217 in this population. Almost three quarters of the patients with DRTB were HIV positive, 218 compared to a prevalence in the population of approximately one quarter. The area of spatial clustering of DRTB was characterised by high HIV prevalence, and is in a similar region to a 219 geographic cluster of HIV positive individuals identified previously.²¹ In this study population, 220 approximately 60% of HIV positive patients were on antiretroviral therapy. Previous studies 221

222 have suggested that improved coverage of antiretroviral therapy at both the individual and community levels can contribute to reducing the incidence of TB.31-33 223 Our study had several limitations. The analysis was restricted to DRTB patients, because we 224 were only able to ascertain cases through hospital admissions data. Drug-sensitive TB 225 226 patients are only admitted when clinically essential whereas policy at the time of the study was for all drug-resistant patients to be admitted for at least one month. We were therefore 227 unable to determine whether the distribution of drug-resistant disease is similar to drug-228 229 sensitive disease. Future studies in this area will integrate additional data from the electronic TB register (ETR.net) to characterise the distribution of drug-sensitive TB. 230 The hospital information system used in this study also did not contain clinical information 231 about history of treatment for TB. With the data available we therefore could not make any 232 233 inference about the balance of primary and secondary drug resistance in the population. 234 However, most recent data from high HIV prevalence settings suggest that, regardless of 235 treatment history, the majority of DRTB cases arise from transmission.³⁴ 236 Another limitation was the use of hospital discharge codes to define DRTB patients, which is 237 an underestimate of the true number. We will have missed patients that were not coded in the hospital data as DRTB; children younger than 12 years who may have been managed 238 239 elsewhere; individuals who had DRTB detected but did not go to hospital, and those with undetected disease. However, we have no reason to suspect that these factors would 240 operate in a geographically heterogeneous way that would lead to spurious spatial clusters. 241 242 The spatial analysis of DRTB in the wider Hlabisa sub-district was limited by use of local 243 areas as opposed to individual addresses. However, results were similar to the analysis of 244 precise point locations in the demographic surveillance area, which suggests that this 245 method may be useful for similar analyses in future. We also used a hospital-based 246 denominator as a proxy for the underlying population in this analysis. This will therefore be 247 influenced by spatial factors which govern the distribution of conditions relating to other admissions. Finally, we described the characteristics of individuals using hospital data, but 248 further information on patients would allow a more detailed analysis of risk factors in this 249 250 population. **CONCLUSIONS** 251 Our study shows concerning evidence of possible ongoing transmission of DRTB in this area 252 253 of high prevalence. This suggests that targeting interventions to spatial areas of highest risk could be effective in supporting progress towards the WHO's End TB strategy for a 90% 254

reduction in new cases by 2035.35

ACKNOWLEDGEMENTS

CMS received funding from the South African MRC Flagship program at the AHRI and University of KwaZulu-Natal, and from the Farr Institute of Health Informatics Research. We thank Petros Khambule for collection of the hospital data, and Kathy Baisley for technical support with data manipulation and analysis. CMS performed the analysis and drafted the manuscript. FT, RL and CMS designed the study. KH oversaw collection of hospital data. All authors contributed to and approved the final manuscript. We have no conflicts of interest to declare.

REFERENCES

- 266 1. World Health Organization. Global Tuberculosis Report 2016. Geneva: 2016.
- 267 2. Statistics South Africa. Mortality and causes of death in South Africa, 2011: Findings from
- death notification. 2014.
- 3. Massyn N, Peer N, English R, Padarath A, Barron P, Day C. District Health Barometer
- 270 2015/16. Durban: Health Systems Trust, 2016.
- 271 4. Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, et al. Nationwide and
- 272 regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004-
- 273 2012: a time series analysis. Lancet Infec Dis. 2016;15:1066-76.
- 5. Smith CM, Le Comber SC, Fry H, Bull M, Leach S, Hayward AC. Spatial methods for infecitous
- disease outbreak investigations: systematic literature review. Euro Surveill. 2015;20(39).
- 276 6. Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, et al. Identifying Hotspots of
- 277 Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. J Infect
- 278 Dis. 2016;213(2):287-94.
- 7. Saavedra-Campos M, Welfare W, Cleary P, Sails A, Burkitt A, Hungerford D, et al. Identifying
- areas and risk groups with localised Mycobacterium tuberculosis transmission in northern England
- from 2010 to 2012: spatiotemporal analysis incorporating highly discriminatory genotyping data.
- 282 Thorax. 2015;71(8):742-8.
- 283 8. Izumi K, Ohkado A, Uchimura K, Murase Y, Tatsumi Y, Kayebeta A, et al. Detection of
- Tuberculosis Infection Hotspots Using Activity Spaces Based Spatial Approach in an Urban Tokyo,
- 285 from 2003 to 2011. PLOS ONE. 2015;10(9):e0138831.
- 286 9. Althomsons SP, Kammerer JS, Shang N, Navin TR. Using Routinely Reported Tuberculosis
- Genotyping and Surveillance Data to Predict Tuberculosis Outbreaks. PLOS ONE. 2012;7(11):e48754.
- 288 10. Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, et al. Assessing spatial
- 289 heterogeneity of MDR-TB in a high burden country. Eur Respir J.
- 290 2013;42(5):10.1183/09031936.0111812.
- 291 11. Lin H, Shin S, Blaya JA, Zhang Z, Cegielski P, Contreras C, et al. Assessing spatiotemporal
- 292 patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting.
- 293 Epidemiol Infect. 2011;139(11):1784-93.
- 294 12. Dissou A, Frank F, N'Dira S, Gladys A, Isdore Chola S, Leen R, et al. Possible Outbreak of
- 295 Streptomycin-Resistant Mycobacterium tuberculosis Beijing in Benin. Emerg Infect Dis.
- 296 2009;15(7):1123.
- 297 13. Smith CM, Maguire H, Anderson C, Macdonald N, Hayward AC. Multiple large clusters of
- 298 tuberculosis in London: a cross-sectional analysis of molecular and spatial data. ERJ Open Res.
- 299 2017;3(1).
- 300 14. Smith CM, Trienekens SC, Anderson C, Lalor MK, Brown T, Story A, et al. Twenty years and
- 301 counting: epidemiology of an outbreak of isoniazid-resistant tuberculosis in England and Wales, 1995
- 302 to 2014. Euro Surveill. 2017;22(8).
- 303 15. Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort
- 304 Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int
- 305 J Epidemiol. 2008;37(5):956-62.
- 306 16. Herbst K, Law M, Geldsetzer P, Tanser F, Harling G, Barnighausen T. Innovations in health
- 307 and demographic surveillance systems to establish the causal impacts of HIV policies. Curr Opin HIV
- 308 AIDS. 2015;10(6):483-94.
- 309 17. Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T. Dramatic increase in HIV prevalence
- after scale-up of antiretroviral treatment. AIDS. 2013;27(14):2301-5.
- 311 18. Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P. Impact of a
- 312 novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa
- 313 (Uchwepheshe): study protocol for a cluster randomised trial. Trials. 2013;14:170.

- 314 19. National Task Team for the Implementation of ICD-10. South African ICD-10 Coding
- 315 Standards, Version 1.06. 2007.
- 316 20. Kulldorff M, Information Management Services Inc. SaTScan[™] v9.4.2: Software for the
- 317 spatial and space-time scan statistics. 2015.
- 318 21. Tanser F, Bärnighausen T, Cooke GS, Newell M-L. Localized spatial clustering of HIV
- infections in a widely disseminated rural South African epidemic. Int J Epidemiol. 2009;38(4):1008-
- 320 16.
- 321 22. Baddeley A, Turner R. spatstat: An R Package for Analyzing Spatial Point Patterns. J Stat
- 322 Softw. 2005;12(6):1-42.
- 323 23. Kleinman K. rsatscan: Tools, Classes, and Methods for Interfacing with SaTScan Stand-Alone
- 324 Software. 0.3.9200 ed2015.
- 325 24. Muhwava W, Hosegood V, Nyirenda M, Herbst K, Newell ML. Levels and determinants of
- migration in rural KwaZulu-Natal, South Africa. Afr Popul Stud. 2010;24(3):259-80.
- 327 25. Yates TA, Tanser F, Abubakar I. Plan Beta for tuberculosis: it's time to think seriously about
- poorly ventilated congregate settings. Int J Tuberc Lung D. 2016;20(1):5-10.
- 329 26. Andrews JR, Morrow C, Walensky RP, Wood R. Integrating social contact and environmental
- data in evaluating tuberculosis transmission in a South African township. J Infect Dis. 2014;210:597-
- 331 603.

354

355

356

357

- 332 27. Chamie G, Wandera B, Marquez C, Kato-Maeda M, Kamya MR, Havlir DV, et al. Identifying
- 333 locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int
- 334 Health. 2015;20:537-45.
- 335 28. Wood R, Racow K, Bekker L-G, Morrow C, Middelkoop K, Mark D, et al. Indoor social
- networks in a South African township: potential contribution of location to tuberculosis
- 337 transmission. PLOS ONE. 2012;7:e39246.
- 338 29. Andrews JR, Morrow C, Wood R. Modeling the role of public transportation in sustaining
- tuberculosis transmission in South Africa. Am J Epidemiol. 2013;177:556-61.
- 30. Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of
- Extensively Drug-Resistant Tuberculosis in South Africa. New Engl J Med. 2017;376(3):243-53.
- 342 31. Hermans S, Boulle A, Caldwell J, Pienaar D, Wood R. Temporal trends in TB notification rates
- during ART scale-up in Cape Town: an ecological analysis. J Int AIDS Soc. 2015;18:20240.
- 344 32. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long
- term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-16.
- 346 33. Middelkoop K, Bekker L-G, Myer L, Whitelaw A, Grant A, Kaplan G, et al. Antiretroviral
- program associated with reduction in untreated prevalent tuberculosis in a South African township.
- 348 Am J Respir Crit Care Med. 2010;182:1080-5.
- 349 34. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology,
- 350 pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-
- resistant, and incurable tuberculosis. The Lancet Respiratory medicine. 2017.
- 35. World Health Organization. The End TB Strategy 2015 [cited 2016 30 August]. Available
- from: http://www.who.int/tb/strategy/en/.

TABLES
 Table 1: Characteristics of drug-resistant tuberculosis patients, Hlabisa hospital (2011-2015)

2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* HIV positive, on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	Characteristic	N	%
Female 250 51.1 Age group (years) 5-14 10 2.0 15-24 59 12.1 12.1 25-34 166 33.9 33.9 35-44 143 29.2 45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 20.9 23.5 2015 96 19.6 Drug-resistant tuberculosis type 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV positive, ART missing 67	Sex		
Age group (years) 5-14 15-24 25-34 166 33.9 35-44 45-54 66 13.5 55-64 27 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 2012 2013 2014 2015 Port of admission 2014 2015 Drug-resistant tuberculosis type MDR Rifampicin monoresistant XDR Site of disease Pulmonary Extrapulmonary Missing HIV/ ART status' HIV positive, not on ART HIV positive, not on ART HIV positive, RAT missing HIV negative 126 126 33.9 12.1 13.5 13.5 13.5 15.7 20.0 20.0 20.0 21.1 22.0 15.7 20.0 22.0 15.7 20.0 23.5 20.0 23.5 20.0 23.5 20.0 23.5 20.0 23.5 20.0 23.5 20.0 21.1 23.5 23.5 20.0 21.1 23.5 24.1 23.5 24.1 86.1 Extrapulmonary 42.1 86.1 86.1 Extrapulmonary 42.1 86.1 1.0 41.3 HIV positive, on ART 13.3 27.2 HIV positive, ART missing HIV negative 67 13.7	Male	239	48.9
5-14 15-24 59 12.1 25-34 166 33.9 35-44 143 29.2 45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 77 15.7 2012 98 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR Rifampicin monoresistant XDR 6 51.2 Site of disease Pulmonary Extrapulmonary Missing 63 HIV/ ART status' HIV positive, not on ART HIV positive, not on ART HIV positive, ART missing HIV regative 67 129 12.1 12.1 12.1 13.3 29.2 14.1 15.7 20.0 20.0 21.1 20.0 20.0 20.0 20.0 20.0	Female	250	51.1
15-24 59 12.1 25-34 166 33.9 35-44 143 29.2 45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' HIV positive, on ART 41.3 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	Age group (years)		
25-34 166 33.9 35-44 143 29.2 45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' HIV positive, on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	5-14	10	2.0
35-44 143 29.2 45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 15.7 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' HIV positive, on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	15-24	59	12.1
45-54 66 13.5 55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' HIV positive, on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	25-34	166	33.9
55-64 27 5.5 65-74 10 2.0 75+ 8 1.6 Year of admission 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type 478 97.8 Rifampicin monoresistant XDR 5 1.0 Site of disease 9ulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' 110 41.3 HIV positive, on ART 202 41.3 HIV positive, ART missing 5 1.0 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	35-44	143	29.2
65-74 10 2.0 75+ 8 1.6 Year of admission 15.7 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type 97.8 MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease 86.1 1.2 Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* 11.0 41.3 HIV positive, on ART 202 41.3 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	45-54	66	13.5
75+ 8 1.6 Year of admission 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type 97.8 MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease 86.1 1.2 Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' 41.3 HIV positive, on ART 202 41.3 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	55-64	27	5.5
Year of admission 2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status' 41.3 27.2 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	65-74	10	2.0
2011 77 15.7 2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* HIV positive, on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	75+	8	1.6
2012 98 20.0 2013 103 21.1 2014 115 23.5 2015 96 19.6 Drug-resistant tuberculosis type MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* HIV positive, on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	Year of admission		
2013	2011	77	15.7
2014 2015 96 19.6 Drug-resistant tuberculosis type MDR Arifampicin monoresistant XDR 6 1.0 Site of disease Pulmonary Extrapulmonary Missing 63 12.9 HIV/ ART status' HIV positive, on ART HIV positive, not on ART HIV positive, ART missing HIV negative 67 11.5 23.5 19.6 23.5 19.6 23.5 19.6 27.8 47.8 47.8 47.8 47.8 47.8 47.8 47.8 4	2012	98	20.0
2015 96 19.6 Drug-resistant tuberculosis type 97.8 MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	2013	103	21.1
Drug-resistant tuberculosis type 478 97.8 MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* 41.3 HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	2014	115	23.5
MDR 478 97.8 Rifampicin monoresistant 5 1.0 XDR 6 1.2 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	2015	96	19.6
Rifampicin monoresistant XDR 5 1.0 Site of disease Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* 41.3 HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing HIV negative 67 13.7	Drug-resistant tuberculosis type		
XDR 6 1.2 Site of disease 86.1 Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status* 41.3 HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	MDR	478	97.8
Site of disease 421 86.1 Pulmonary 5 1.0 Extrapulmonary 63 12.9 HIV/ ART status* 41.3 HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	Rifampicin monoresistant	5	1.0
Pulmonary 421 86.1 Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status*	XDR	6	1.2
Extrapulmonary 5 1.0 Missing 63 12.9 HIV/ ART status*	Site of disease		
Missing 63 12.9 HIV/ ART status* HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	Pulmonary	421	86.1
HIV/ ART status* HIV positive, on ART HIV positive, not on ART HIV positive, ART missing HIV positive, ART missing HIV negative 67 13.7	Extrapulmonary	5	1.0
HIV positive, on ART 202 41.3 HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	Missing	63	12.9
HIV positive, not on ART 133 27.2 HIV positive, ART missing 5 1.0 HIV negative 67 13.7	HIV/ ART status*		
HIV positive, ART missing 5 1.0 HIV negative 67 13.7	HIV positive, on ART	202	41.3
HIV negative 67 13.7	HIV positive, not on ART	133	27.2
	HIV positive, ART missing	5	1.0
Missing 82 16.8	HIV negative	67	13.7
	Missing	82	16.8

Discharge status		
Discharged	394	80.6
Transferred	12	2.5
Died	78	16.0
Absconded	5	1.0

MDR, multidrug-resistant; XDR, extensively drug-resistant; HIV, human immunodeficiency virus; ART, antiretroviral therapy.

*at time of hospital admission

FIGURES

Figure 1: Study site

A: Location of Hlabisa sub-district within South Africa

B: Hlabisa sub-district, showing local areas and Africa Health Research Institute demographic surveillance area (shaded)

C: Africa Health Research Institute demographic surveillance area, with roads and approximate locations of homesteads (incorporating intentional random error)















